Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138812 | 0.86 | CYP2D6 (0.38) | PTPN11 | |
| SCHEMBL21138254 | 0.86 | CYP2D6 (0.38) | PTPN11 | |
| SCHEMBL21138897 | 0.85 | PTPN11 (0.36) | PTPN11 | |
| SCHEMBL21138852 | 0.85 | GRIA1 (0.40) | GRIA1PTPN11EIF2AK4 | |
| SCHEMBL21138814 | 0.81 | ADORA3 (0.37) | PTPN11 | |
| SCHEMBL21138580 | 0.81 | ADORA3 (0.37) | PTPN11 | |
| SCHEMBL21138292 | 0.81 | ADORA3 (0.37) | PTPN11 | |
| SCHEMBL21138258 | 0.77 | PTPN11 (0.39) | PTPN11 | |
| SCHEMBL21138813 | 0.76 | PTPN11 (0.41) | PTPN11 | |
| SCHEMBL21138574 | 0.74 | PTPN11 (0.37) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | GRIA1 2936/4885PTPN11 497/4885EIF2AK4 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.